title: [Primary results of antiretroviral treatment among HIV/AIDS infected children in Lomé (Togo)].
abstract: Since 2004 in Togo HIV/AIDS infected children have, free of charge, access to antiretroviral drugs according to the national program. The aim of this study was to investigate the clinical, biological and prognosis aspects of anti-retroviral treatment on HIV/AIDS infected children.
  
  
  METHODS
  We conducted a cross sectional study on 72 HIV/AIDS infected children with anti-retroviral treatment, under the supervision of clinicians within 3 associations specialized in the management of subjects infected by HIV/SIDA at Lomé (Togo).
  
  
  RESULTS
  The average age of children was 6 years 9 months. The middle age to HIV screening was 4 years 2 months. The sex ratio was 1.05. The majority of these children (79.2%) were orphans of at least 1 of their parents. All the children were stemmed from families with modest income. The transmission mother to child was the way of HIV contamination found among all the children. To a certain extent, all the children were infected by the HIV 1. Most of the children (66.7%) receiving an antiretroviral treatment for at least 6 months were asymptomatic and had no more immunodeficiency. After 15 months, the children have gained 464 CD4/mm(3). The initial protocols antiretroviral prescribed among children were: zidovudine-lamivudine-abacavir (36.1%), lamivudine-didanosine-nevirapine (30.5%), lamivudine-stavudine-nevirapine (29.2%), zidovudine-lamivudine-didanosine (4.2%). The digestive disorders have been the first side effects (83.4%). The rate of good observance was middle (51%) and lowered with the increased age of children, and the period of the anti-retroviral treatment.
  
  
  CONCLUSIONS
  Antiretroviral treatment among HIV/AIDS infected children is giving good results in Togo. But many efforts remain to increase the number of beneficiaries.
authors.affiliation: Département de pédiatrie, CHU de Tokoin, BP 57, Lomé, Togo. yatakouma@yahoo.fr
authors.forename: D-Y
authors.initials: DY
authors.lastname: Atakouma
authors.forename: E
authors.initials: E
authors.lastname: Tsolenyanu
authors.forename: A
authors.initials: A
authors.lastname: Gbadoe
authors.forename: V
authors.initials: V
authors.lastname: Gbetoglo
authors.forename: K
authors.initials: K
authors.lastname: Lawson-Evi
authors.forename: A-R
authors.initials: AR
authors.lastname: Agbere
authors.forename: K
authors.initials: K
authors.lastname: Tatagan-Agbi
authors.forename: K
authors.initials: K
authors.lastname: Assimadi
mesh_terms: D000293:Adolescent; D044966:Anti-Retroviral Agents / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D002648:Child; D002675:Child, Preschool; D003430:Cross-Sectional Studies; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000635:transmission; D006801:Humans; D018445:Infectious Disease Transmission, Vertical; D008297:Male; D014037:Togo / Q000453:epidemiology
chemical_list: D044966:Anti-Retroviral Agents